Tag: Inventiva
Inventiva: planned presentation at the 83rd Scientific Sessions of the American Diabetes Association
By Alexandra Saintpierre Published on 06/26/2023 at 07:24 Photo credit © Inventiva (Boursier.com) — inventive announces the selection…
Inventiva announces 5 scientific presentations at EASL INTERNATIONAL LIVER CONGRESS 2023
(Boursier.com) — inventive a biopharmaceutical company specializing in the clinical development of orally administered small molecules for the treatment of nonalcoholic steatohepatitis and other diseases with unmet medical need, today…
Inventiva and Echosens launch a joint initiative to raise awareness about NASH and facilitate access to screening for patients at risk
By Claude Leguilloux Published on 08/06/2023 at 08:42 Photo credit © ChaunuPictures (Boursier.com) — inventive a biopharmaceutical company…
Inventiva joins forces with Echosens to raise awareness about Nash, liver disease – 06/08/2023 at 10:10
(AOF) – Inventiva joins forces with Echosens, the designer of Fibroscan, a diagnostic solution for liver health, to “raise awareness of NASH (non-alcoholic steatohepatitis) and facilitate access to screening for…
Inventiva: a net loss widened in 2022
(CercleFinance.com) – The specialist in non-alcoholic steatohepatitis Inventiva has published net income for the year 2022 of -54.3 million euros, compared to -49.6 million for 2021, due in particular to…
Inventiva: annual publication in sight
By Alexandra Saintpierre Published on 03/27/2023 at 07:18 Photo credit © Inventiva (Boursier.com) — The 2022 financial…
Inventiva announces the date of publication and presentation of its 2022 financial results – 03/23/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva announces the date of publication and presentation of its 2022 financial results – 03/23/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: preliminary financial results for 2022
By Alexandra Saintpierre Published on 02/14/2023 at 22:22 Photo credit © SunocciPictures (Boursier.com) — The turnover ofinventive…
Half-year report on the liquidity contract of Inventiva entered into with Kepler Cheuvreux – 01/30/2023 at 10:00 p.m.
Daix (France), Long Island City (New York, United States), January 30, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of…
Inventiva: under pressure
Through Claude Leguilloux Published on 06/01/2023 at 09:28 Photo credit © ChaunuPictures (Boursier.com)…
Inventiva received 25 million euros from the EIB for the 1st tranche of a loan – 12/12/2022 at 10:14
(AOF) – Inventiva, a biopharmaceutical company specialized in the clinical development of small molecules administered orally for the treatment of non-alcoholic steatohepatitis (“NASH”), announces today that it has received the…